X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Cipla with Dishman Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs DISHMAN PHARMA - Comparison Results

CIPLA    Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DISHMAN PHARMA 
   Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CIPLA DISHMAN PHARMA CIPLA/
DISHMAN PHARMA
 
P/E (TTM) x 44.3 25.1 176.5% View Chart
P/BV x 3.9 3.3 115.5% View Chart
Dividend Yield % 0.3 0.7 50.0%  

Financials

 CIPLA   DISHMAN PHARMA
EQUITY SHARE DATA
    CIPLA
Mar-17
DISHMAN PHARMA
Mar-16
CIPLA/
DISHMAN PHARMA
5-Yr Chart
Click to enlarge
High Rs622374 166.1%   
Low Rs458129 355.5%   
Sales per share (Unadj.) Rs181.9197.8 91.9%  
Earnings per share (Unadj.) Rs12.921.2 60.7%  
Cash flow per share (Unadj.) Rs29.334.7 84.4%  
Dividends per share (Unadj.) Rs2.002.00 100.0%  
Dividend yield (eoy) %0.40.8 46.6%  
Book value per share (Unadj.) Rs155.7179.9 86.5%  
Shares outstanding (eoy) m804.5180.69 997.0%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x3.01.3 233.4%   
Avg P/E ratio x42.011.9 353.6%  
P/CF ratio (eoy) x18.47.2 254.2%  
Price / Book Value ratio x3.51.4 248.0%  
Dividend payout %15.59.4 164.8%   
Avg Mkt Cap Rs m434,51620,306 2,139.9%   
No. of employees `00023.00.8 2,779.6%   
Total wages/salary Rs m26,3385,355 491.9%   
Avg. sales/employee Rs Th6,349.119,252.7 33.0%   
Avg. wages/employee Rs Th1,143.06,459.5 17.7%   
Avg. net profit/employee Rs Th449.32,064.1 21.8%   
INCOME DATA
Net Sales Rs m146,30215,961 916.7%  
Other income Rs m2,287265 861.7%   
Total revenues Rs m148,58916,226 915.8%   
Gross profit Rs m24,7584,103 603.4%  
Depreciation Rs m13,2291,091 1,213.0%   
Interest Rs m1,594944 168.8%   
Profit before tax Rs m12,2222,334 523.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m-701 -6,354.5%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,798624 288.3%   
Profit after tax Rs m10,3541,711 605.1%  
Gross profit margin %16.925.7 65.8%  
Effective tax rate %14.726.7 55.0%   
Net profit margin %7.110.7 66.0%  
BALANCE SHEET DATA
Current assets Rs m87,37011,018 793.0%   
Current liabilities Rs m33,0819,517 347.6%   
Net working cap to sales %37.19.4 394.6%  
Current ratio x2.61.2 228.1%  
Inventory Days Days87110 78.7%  
Debtors Days Days6235 178.9%  
Net fixed assets Rs m111,56716,304 684.3%   
Share capital Rs m1,609161 996.9%   
"Free" reserves Rs m123,64512,907 958.0%   
Net worth Rs m125,25414,516 862.9%   
Long term debt Rs m36,4544,189 870.1%   
Total assets Rs m209,53229,805 703.0%  
Interest coverage x8.73.5 249.7%   
Debt to equity ratio x0.30.3 100.8%  
Sales to assets ratio x0.70.5 130.4%   
Return on assets %5.78.9 64.0%  
Return on equity %8.311.8 70.1%  
Return on capital %8.517.5 48.5%  
Exports to sales %34.224.8 138.0%   
Imports to sales %8.33.7 223.2%   
Exports (fob) Rs m50,0503,956 1,265.1%   
Imports (cif) Rs m12,203596 2,046.4%   
Fx inflow Rs m51,0664,952 1,031.3%   
Fx outflow Rs m17,678697 2,537.0%   
Net fx Rs m33,3884,255 784.7%   
CASH FLOW
From Operations Rs m23,8242,786 855.0%  
From Investments Rs m-13,127-1,529 858.6%  
From Financial Activity Rs m-13,239-941 1,406.7%  
Net Cashflow Rs m-2,478316 -783.2%  

Share Holding

Indian Promoters % 16.0 61.4 26.1%  
Foreign collaborators % 20.8 0.0 -  
Indian inst/Mut Fund % 12.2 3.7 329.7%  
FIIs % 23.7 12.7 186.6%  
ADR/GDR % 1.1 0.0 -  
Free float % 26.2 22.1 118.6%  
Shareholders   161,166 46,261 348.4%  
Pledged promoter(s) holding % 0.0 35.8 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CIPLA With:   SUVEN LIFE  SUN PHARMA  PFIZER  FDC LTD.  SHASUN PHARMA  

Compare CIPLA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Of Global Markets Hitting Record Highs and Top Stocks in Action During the Week(RoundUp)

Global stock markets ended the week on a positive note. Benchmark indices in US grew by 1% during the week. The Down Jones Industrial Average topped the 26,000.

Related Views on News

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Cipla: Extraordinary Income Boosts Net Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

Proceeds from the sale of the South African animal business bolstered Cipla's net profits for the quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


Jan 19, 2018 (Close)

TRACK CIPLA

CIPLA - ELDER PHARMA COMPARISON

COMPARE CIPLA WITH

MARKET STATS